All AbMole products are for research use only, cannot be used for human consumption.
8-OH-DPAT (8-Hydroxy-DPAT) is a potent and selective 5-HT agonist, with a pIC50 of 8.19 for 5-HT1A. 8-OH-DPAT has high affinity at 5-HT7 with a Ki of 466 nM.
In vivo, 8-OH-DPAT (1 mg/kg) significantly increases wakefulness and reduces the duration of REM sleep without effect on the duration of non-REM sleep in the dark period in orexin knockout (KO) mice. 8-OH-DPAT (1 mg/kg, s.c.) activates 5-HT1A receptor in orexin knockout mice.
| Cell Experiment | |
|---|---|
| Cell lines | Retinal pigment epithelial (RPE) cells |
| Preparation method | Cells are exposed to H2O2 (200 µM) for 1 hour and either pre-or post treated with 8-OH DPAT (10 µM) for 24 hours. In the case of pretreatment all measurements are made 24 hr after H2O2 and for post treatment 8-OH DPAT is added immediately following H2O2 exposure. 5HT1A agonist treatment: To assess the ability of the 5-HT1A receptor agonist, 8-OH DPAT, to reduce lipofuscin formation in cultured RPE cells, this compound is added to the culture medium every 48 hours at concentrations ranging from 0.1 to 20 µM. All experiments are undertaken in basal medium, and cells receiving vehicle alone (PBS) acted as negative controls. To determine if the effect of 8-OH DPAT is sustained following discontinuation of 5-HT1A receptor agonist treatment, 8-OH DPAT treatment is discontinued after 28 days and the cells maintained in basal medium or fed POS for a further 28 days. To assess the ability of 8-OH DPAT to remove existing lipofuscin, autophagy-derived lipofuscin and phagocytic-derived lipofuscin are allowed to accumulate as described above and then 8-OH DPAT is added every second day for up to 28 days. |
| Concentrations | 10 μM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Male Lister hooded rats |
| Formulation | isotonic saline |
| Dosages | 0, 3.0, 10, 100 and 300 μg/kg |
| Administration | i.p. |
| Molecular Weight | 247.38 |
| Formula | C16H25NO |
| CAS Number | 78950-78-4 |
| Solubility (25°C) | DMSO: ≥ 45 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Animal Modeling Products |
|---|
| Doxorubicin HCL
Doxorubicin HCl (Adriamycin, DOX, RP 13057) hydrochloride is an antibiotic-like agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis. |
| Streptozotocin
Streptozotocin (STZ) is a kind of glucosamine - nitrosourea derivative. *The compound is unstable in solutions, freshly prepared is recommended |
| Bleomycin sulfate
Bleomycin sulfate (Blenoxane) is a glycopeptide antitumor antibiotic isolated from Streptomyces verticillus. |
| Loperamide hydrochloride
Loperamide hydrochloride is a high affinity μ-opioid receptor agonist with peripheral selectivity with Ki values of 2, 48 and 1156 nM for μ-, δ- and κ-opioid receptors respectively. Loperamide hydrochloride is also a selective and competitive human intestinal carboxylesterases (hiCE) inhibitor. It can be used to construct animal models of functional constipation. |
| Imiquimod
Imiquimod (R837), an imidazoquinoline amine analog to guanosine, is a selective toll like receptor 7 (TLR7) agonist. with potent indirect antiviral activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
